New treatments for atopic dermatitis
Atopic dermatitis now affects 15% to 20% of chil dren in developed countries, and prevalence in cities in developing countries undergoing rapid demographic changes is quickly following suit.1 Most cases of atopic dermatitis in a given community are mild, but children with moderate to severe di...
| Main Author: | |
|---|---|
| Format: | Article |
| Published: |
BMJ Publishing Group
2002
|
| Online Access: | https://eprints.nottingham.ac.uk/862/ |
| _version_ | 1848790493357408256 |
|---|---|
| author | Williams, Hywel |
| author_facet | Williams, Hywel |
| author_sort | Williams, Hywel |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Atopic dermatitis now affects 15% to 20% of chil
dren in developed countries, and prevalence
in cities in developing countries undergoing
rapid demographic changes is quickly following suit.1
Most cases of atopic dermatitis in a given community
are mild, but children with moderate to severe disease
can have continuous itching and associated loss of
sleep. The social stigma of a visible skin disease can also
be soul destroying for both patient and family. A few
studies have suggested that some degree of prevention
of the disease is possible,2 although these measures
have not been taken up widely. In the absence of any
treatment that is known to alter the clinical course of
the disease, most treatment is aimed at reducing symp
toms and signs. After a relative lull of almost 40 years,
new drugs—tacrolimus and pimecrolimus—have
appeared that offer different approaches to managing
this miserable disease. Do they work? Are they safe?
And how do they compare with existing treatments? |
| first_indexed | 2025-11-14T18:13:29Z |
| format | Article |
| id | nottingham-862 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T18:13:29Z |
| publishDate | 2002 |
| publisher | BMJ Publishing Group |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-8622020-05-04T16:25:36Z https://eprints.nottingham.ac.uk/862/ New treatments for atopic dermatitis Williams, Hywel Atopic dermatitis now affects 15% to 20% of chil dren in developed countries, and prevalence in cities in developing countries undergoing rapid demographic changes is quickly following suit.1 Most cases of atopic dermatitis in a given community are mild, but children with moderate to severe disease can have continuous itching and associated loss of sleep. The social stigma of a visible skin disease can also be soul destroying for both patient and family. A few studies have suggested that some degree of prevention of the disease is possible,2 although these measures have not been taken up widely. In the absence of any treatment that is known to alter the clinical course of the disease, most treatment is aimed at reducing symp toms and signs. After a relative lull of almost 40 years, new drugs—tacrolimus and pimecrolimus—have appeared that offer different approaches to managing this miserable disease. Do they work? Are they safe? And how do they compare with existing treatments? BMJ Publishing Group 2002-06-29 Article PeerReviewed Williams, Hywel (2002) New treatments for atopic dermatitis. British Medical Journal, 324 . pp. 1533-1534. |
| spellingShingle | Williams, Hywel New treatments for atopic dermatitis |
| title | New treatments for atopic dermatitis |
| title_full | New treatments for atopic dermatitis |
| title_fullStr | New treatments for atopic dermatitis |
| title_full_unstemmed | New treatments for atopic dermatitis |
| title_short | New treatments for atopic dermatitis |
| title_sort | new treatments for atopic dermatitis |
| url | https://eprints.nottingham.ac.uk/862/ |